The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Should we treat newly diagnosed patients with CLL differently after ASH 2019?
Featured:
Astrid PavlovskyDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Astrid Pavlovsky, Fundaleu CHP, Buenos Aires, AR. We asked: Should we treat newly diagnosed patients with chronic lymphocytic leukemia differently after ASH 2019?
Astrid Pavlovsky talks about the importance of genetic characterization of CLL to guide patient treatment pathway. She also discusses the results of the ELEVATE trial, that examines a new treatment option for elderly patients with CLL.
Should we treat newly diagnosed patients with CLL differently after ASH 2019?